Cellectis CLLS
NASDAQ CLLS
$0.99 0.00 (-0.11%)
As of: Oct 21, 2026 · 2:56 PM EDT

Cellectis (CLLS) Capital Leases (2021 - 2024)

Updated

Cellectis (CLLS) posted Capital Leases of $89,000 for Q1 2022, compared with -$88,000 a year earlier and down 99.5% from the prior quarter.

Analysis

Cellectis (CLLS) Capital Leases (2021 - 2024) Analysis & Trends

At the end of FY2021, Cellectis' Capital Leases came in at $17.51 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,137.36 Bn 1,105.95 Bn 19.71 Bn
2 Johnson & Johnson 617.62 Bn 536.15 Bn 17.26 Bn
3 AbbVie 501.17 Bn 474.28 Bn 12.70 Bn
4 Merck 368.13 Bn 322.51 Bn 12.21 Bn
5 Novartis Ag 297.75 Bn 261.74 Bn 11.24 Bn
6 Astrazeneca 261.23 Bn 234.92 Bn 12.86 Bn
7 Amgen 236.68 Bn 192.08 Bn 7.24 Bn
8 Gilead Sciences 190.97 Bn 165.17 Bn 6.22 Bn
9 Pfizer 169.72 Bn 116.36 Bn 10.94 Bn
10 Cellectis 94.28 Mn -659.11 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2024 98.26 Mn
Jun 30, 2024 96.71 Mn
Dec 31, 2023 92.07 Mn
Mar 31, 2022 89,000.00
Dec 31, 2021 17.51 Mn
API Access

Cellectis Capital Leases API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=capital-leases&ticker=CLLS&period=max&api_key=YOUR_API_KEY